Cash Flow Statement

Amortization of Deferred Charges Amortization of Deferred Charges Amortizatization of Intangibles Amortizatization of Intangibles Asset Writedowns and Impairment Asset Writedowns and Impairment Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Accured Expenses Change in Accured Expenses Change in Cash Change in Inventory Change in Inventory Change in Receivables Change in Receivables Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Dividends Paid - Common Dividends Paid - Common Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Gains from Sales and Divestitures Gains from Sales and Divestitures Long-Term Debt Repayments Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other Working Capital Changes Other Working Capital Changes Other financing activities Other financing activities Sales of Property, Plant and Equipment Sales of Property, Plant and Equipment Share-based Compensation Share-based Compensation Shares Issued

Daily Values

Growth Metrics

Others

Accumulated Depreciation & Amortization Accumulated Depreciation & Amortization Cost of Revenue EBIAT Gross Profit Leases Long-Term Debt Repayments Machine, Furnitures, Fixtures & Other Other Gross PP&E Adjustments Other Gross PP&E Adjustments Property, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - Net Shares Issued Shares Outstanding Shares Outstanding

ENDRA Life Sciences (NDRA) Long-Term Debt Issuances (2016 - 2019)

ENDRA Life Sciences has reported Long-Term Debt Issuances over the past 4 years, most recently at $2.5 million for Q3 2019.

Quarterly Long-Term Debt Issuances changed N/A to $2.5 million in Q3 2019 from the year-ago period, while the trailing twelve-month figure was $2.5 million through Dec 2020, changed 0.0% year-over-year, with the annual reading at $2.5 million for FY2019, 166.28% up from the prior year.
Long-Term Debt Issuances was $2.5 million for Q3 2019 at ENDRA Life Sciences, up from $935300.0 in the prior quarter.
Over five years, Long-Term Debt Issuances peaked at $2.5 million in Q3 2019 and troughed at -$1.3 million in Q4 2016.
The 4-year median for Long-Term Debt Issuances is $580150.0 (2017), against an average of $616800.2.
The largest YoY upside for Long-Term Debt Issuances was 350.0% in 2017 against a maximum downside of 350.0% in 2017.
A 4-year view of Long-Term Debt Issuances shows it stood at -$1.3 million in 2016, then skyrocketed by 116.84% to $225000.0 in 2017, then soared by 315.69% to $935300.0 in 2018, then surged by 166.28% to $2.5 million in 2019.
Per Business Quant, the three most recent readings for NDRA's Long-Term Debt Issuances are $2.5 million (Q3 2019), $935300.0 (Q2 2018), and $225000.0 (Q1 2017).